The Prostate Oncology Program is an interdisciplinary group of 34 laboratory, translational and clinical researchers from 11 departments and four schools with over $13 million in annual direct research support including nearly $4 million from the NCI. The Prostate Oncology Program, formerly the Urologic Oncology Program, was renamed during this grant period to reflect Its primary mission and critical mass of strength In translating basic and clinical discoveries in prostate cancer into effective medical solutions. The program includes a Prostate SPORE (recently renewed), a PO1 on the Biology of Prostate Cancer Bone Metastasis (recently renewed), a recently renewed Department of Defense funded Prostate Cancer Clinical trials Consortium site (DOD-PCCTC), a prostate-focused Early Disease Research Network (EDRN) site (new this period) and a NIDDK training grant In Clinical and Translational Research Training in Urology (T32). Over this grant period the 34 program members published 563 publications of which 27,9% are intraprogrammatic and 31.3% are Inter-programmatic collaborations. The Program is committed to creating and sustaining a multidisciplinary environment for basic and clinical researchers studying prostate cancer. The scientific aims of the Prostate Oncology Programs are 1) to investigate the genetic and epigenetic events that contribute to malignant transformation in prostate cancer, 2) to characterize aberrations in the tumor microenvironment that facilitate the growth or metastasis of prostate cancer, 3) to translate basic scientific discoveries to develop new biomarkers and therapies in urologic cancers, and 4) to evaluate clinical outcomes with the purpose of guiding therapy development while reducing cancer-related mortality as well as cancer and therapy-associated morbidity. Among the most high Impact research conducted during this grant period were the seminal findings related to the discovery of TMPRSS-ETS fusions in prostate cancer by program members. The objective of the Prostate Oncology Program Is to understand the biology of prostate cancer and to use this information to develop new tools for the detection, diagnosis, prevention, and treatment of prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046592-24
Application #
8300276
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-06-01
Project End
2017-05-31
Budget Start
2012-09-21
Budget End
2013-05-31
Support Year
24
Fiscal Year
2012
Total Cost
$366,736
Indirect Cost
$130,744
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Verhaegen, Monique E; Mangelberger, Doris; Harms, Paul W et al. (2015) Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. J Invest Dermatol 135:1415-24
Chinn, Steven B; Darr, Owen A; Owen, John H et al. (2015) Cancer stem cells: mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck 37:317-26
Vainshtein, Jeffrey M; Spector, Matthew E; Stenmark, Matthew H et al. (2014) Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:234-9
Castro, Maria G; Candolfi, Marianela; Wilson, Thomas J et al. (2014) Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther 14:1241-57
Vainshtein, Jeffrey M; Spector, Matthew E; McHugh, Jonathan B et al. (2014) Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:513-9
Grogan, Patrick T; Sarkaria, Jann N; Timmermann, Barbara N et al. (2014) Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs 32:604-17
VanderVeen, Nathan; Paran, Christopher; Appelhans, Ashley et al. (2014) Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev 1:
Krook, Melanie A; Nicholls, Lauren A; Scannell, Christopher A et al. (2014) Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma. Mol Cancer Res 12:953-64
Ro, Seung-Hyun; Semple, Ian A; Park, Haewon et al. (2014) Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of p62/sequestosome-1. FEBS J 281:3816-27
Stenmark, Matthew H; McHugh, Jonathan B; Schipper, Matthew et al. (2014) Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys 88:580-8

Showing the most recent 10 out of 862 publications